Anti-dCD20c1-mIgG2a

Monoclonal mouse IgG2a antibody against dog CD20

Anti-dCD20c1-mIgG2a is a mouse monoclonal antibody that specifically targets dog CD20 (dCD20).
In flow cytometry applications, this antibody has exhibited weak cross-reactivity with human CD20. Reactivity with other species has not been tested.

Anti-dCD20c1-mIgG2a was generated by DNA immunization.

This antibody has been screened for the ability to bind dCD20 and induce complement-dependent cytotoxicity (CDC). It is produced by hybridoma cells and purified by affinity chromatography with protein A.

This antibody is not suitable for immunohistochemical staining.

Specifications

Clonality: Monoclonal antibody

Specificity: Targets cells expressing dog CD20

Isotype: Mouse IgG2a, kappa

Clone: 6C12

Formulation: 0.2 µm filtered solution in 68 mM phosphate buffer with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Quality control:

• The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is confirmed by using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
• The antibody is validated for flow cytometry using cells that stably express dog CD20.

Applications: B-cell depletion, flow cytometry

Contents

100 µg purified anti-dCD20c1-mIgG2a antibody, provided azide-free and lyophilized.

Product is shipped at room temperature.

Store lyophilized antibody at -20°C.

Description

CD20 is a transmembrane phosphoprotein that is expressed on the surface of B lymphocytes. The CD20 antigen is present on both resting and activated B lymphocytes but is lost prior to differentiation into plasma cells.

As CD20 expression is restricted to B cells, this antigen is a useful marker or target for B-cell lymphomas [1]. Studies demonstrate that the expression of CD20 correlates with B-cell lymphoma in dogs [2]. In human medicine, an anti-human CD20 monoclonal antibody (Rituximab) has been approved by the FDA to treat B-cell non-Hodgkin's lymphoma resistant to other chemotherapy regimens.

This antibody was tested for B-cell binding and depletion in canine B-cells ex vivo; however, this human therapeutic is not able to bind or deplete canine B-cells [3, 4]. Thus, there is a need for specific antibodies directed against dog CD20. Such antibodies can be used to investigate CD20 as a therapeutic target in canine lymphoma.

1. Kosmas C. et al., 2002. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 16(10):2004-15.
2. Jubala C. et al., 2005. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Vet. Path. 42:468-76.
3. Crow S., 2008. Chemoimmunotherapy for canine lymphoma: tumor vaccines and monoclonal antibodies. Cancer Therapy 6;181-6.
4. Impellizeri J. et al., 2006. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet. J. 171:556-8.